{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:29:47Z","timestamp":1793644187263,"version":"4.5.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T00:00:00Z","timestamp":1646352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T00:00:00Z","timestamp":1646352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1038\/s41390-022-01986-0","type":"journal-article","created":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T14:02:32Z","timestamp":1646402552000},"page":"1911-1915","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Treatment of severe Kaposiform lymphangiomatosis positive for NRAS mutation by MEK inhibition"],"prefix":"10.1038","volume":"94","author":[{"given":"Guy","family":"Chowers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gadi","family":"Abebe-Campino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Golan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asaf","family":"Vivante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoshana","family":"Greenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michalle","family":"Soudack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galia","family":"Barkai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilana","family":"Fox-Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"March","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Battig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakon","family":"Hakonarson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoav","family":"Dori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0427-571X","authenticated-orcid":false,"given":"Adi","family":"Dagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,4]]},"reference":[{"key":"1986_CR1","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jpeds.2013.10.013","volume":"164","author":"SE Croteau","year":"2014","unstructured":"Croteau, S. E. et al. Kaposiform lymphangiomatosis: a distinct aggressive lymphatic anomaly. J. Pediatr. 164, 383\u2013388 (2014).","journal-title":"J. Pediatr."},{"key":"1986_CR2","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.jvsv.2020.03.013","volume":"8","author":"JJ Bundy","year":"2020","unstructured":"Bundy, J. J. et al. Thoracic duct embolization in Kaposiform lymphangiomatosis. J. Vasc. Surg. Venous Lymphat. Disord. 8, 864\u2013868 (2020).","journal-title":"J. Vasc. Surg. Venous Lymphat. Disord."},{"key":"1986_CR3","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1089\/wound.2018.0850","volume":"8","author":"M Ozeki","year":"2019","unstructured":"Ozeki, M. & Fukao, T. Generalized lymphatic anomaly and Gorham-Stout disease: overview and recent insights. Adv. Wound Care 8, 230\u2013245 (2019).","journal-title":"Adv. Wound Care"},{"key":"1986_CR4","doi-asserted-by":"publisher","first-page":"e28529","DOI":"10.1002\/pbc.28529","volume":"67","author":"J Crane","year":"2020","unstructured":"Crane, J. et al. Kaposiform lymphangiomatosis treated with multimodal therapy improves coagulopathy and reduces blood angiopoietin-2 levels. Pediatr. Blood Cancer 67, e28529 (2020).","journal-title":"Pediatr. Blood Cancer"},{"key":"1986_CR5","doi-asserted-by":"publisher","first-page":"e27790","DOI":"10.1002\/pbc.27790","volume":"66","author":"E Boscolo","year":"2019","unstructured":"Boscolo, E. et al. Signaling pathways and inhibitors of cells from patients with Kaposiform lymphangiomatosis. Pediatr. Blood Cancer 66, e27790 (2019).","journal-title":"Pediatr. Blood Cancer"},{"key":"1986_CR6","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s10456-018-9595-8","volume":"21","author":"E Manevitz-Mendelson","year":"2018","unstructured":"Manevitz-Mendelson, E. et al. Somatic NRAS mutation in patient with generalized lymphatic anomaly. Angiogenesis 21, 287\u2013298 (2018).","journal-title":"Angiogenesis"},{"key":"1986_CR7","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1038\/s41436-018-0390-0","volume":"21","author":"SF Barclay","year":"2019","unstructured":"Barclay, S. F. et al. A somatic activating NRAS variant associated with Kaposiform lymphangiomatosis. Genet. Med. 21, 1517\u20131524 (2019).","journal-title":"Genet. Med."},{"key":"1986_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1191-5","volume":"14","author":"M Ozeki","year":"2019","unstructured":"Ozeki, M. et al. Detection of NRAS mutation in cell-free DNA biological fluids from patients with Kaposiform lymphangiomatosis. Orphanet J. Rare Dis. 14, 215 (2019).","journal-title":"Orphanet J. Rare Dis."},{"key":"1986_CR9","doi-asserted-by":"publisher","first-page":"e12324","DOI":"10.15252\/emmm.202012324","volume":"12","author":"JB Foster","year":"2020","unstructured":"Foster, J. B. et al. Kaposiform lymphangiomatosis effectively treated with MEK inhibition. EMBO Mol. Med. 12, e12324 (2020).","journal-title":"EMBO Mol. Med."},{"key":"1986_CR10","doi-asserted-by":"crossref","unstructured":"Dori, Y. et al. Severe lymphatic disorder resolved with MEK inhibition in a patient with Noonan syndrome and Sos1 mutation. Pediatrics 146, e20200167 (2020).","DOI":"10.1542\/peds.2020-0167"},{"key":"1986_CR11","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/s41591-019-0479-2","volume":"25","author":"D Li","year":"2019","unstructured":"Li, D. et al. Araf recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor. Nat. Med. 25, 1116\u20131122 (2019).","journal-title":"Nat. Med."},{"key":"1986_CR12","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1002\/pbc.25422","volume":"62","author":"Z Wang","year":"2015","unstructured":"Wang, Z. et al. Successful treatment of Kaposiform lymphangiomatosis with sirolimus. Pediatr. Blood Cancer 62, 1291\u20131293 (2015).","journal-title":"Pediatr. Blood Cancer"},{"key":"1986_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01893-3","volume":"16","author":"J Zhou","year":"2021","unstructured":"Zhou, J., Yang, K., Chen, S. & Ji, Y. Sirolimus in the treatment of Kaposiform lymphangiomatosis. Orphanet J. Rare Dis. 16, 260 (2021).","journal-title":"Orphanet J. Rare Dis."},{"key":"1986_CR14","doi-asserted-by":"publisher","first-page":"e20153257","DOI":"10.1542\/peds.2015-3257","volume":"137","author":"DM Adams","year":"2016","unstructured":"Adams, D. M. et al. Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies. Pediatrics 137, e20153257 (2016).","journal-title":"Pediatrics"},{"key":"1986_CR15","doi-asserted-by":"crossref","unstructured":"Ricci, K. W. & Iacobas, I. How we approach the diagnosis and management of complex lymphatic anomalies. Pediatr. Blood Cancer e28985 (2021).","DOI":"10.22541\/au.160610607.76247655\/v1"},{"key":"1986_CR16","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1158\/1535-7163.MCT-10-1099","volume":"10","author":"SV Bhagwat","year":"2011","unstructured":"Bhagwat, S. V. et al. Preclinical characterization of Osi-027, a potent and selective inhibitor of Mtorc1 and Mtorc2: distinct from rapamycin. Mol. Cancer Ther. 10, 1394\u20131406 (2011).","journal-title":"Mol. Cancer Ther."},{"key":"1986_CR17","doi-asserted-by":"crossref","unstructured":"Nozawa, A. et al. Characterization of Kaposiform lymphangiomatosis tissue-derived cells. Pediatr. Blood Cancer e29086 (2021).","DOI":"10.1002\/pbc.29086"},{"key":"1986_CR18","doi-asserted-by":"publisher","first-page":"e495","DOI":"10.1097\/MPH.0000000000001284","volume":"40","author":"K Glaser","year":"2018","unstructured":"Glaser, K., Dickie, P. & Dickie, B. H. Proliferative cells from Kaposiform lymphangiomatosis lesions resemble mesenchyme stem cell-like pericytes defective in vessel formation. J. Pediatr. Hematol. Oncol. 40, e495\u2013e504 (2018).","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"1986_CR19","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1046\/j.1525-1470.1999.00103.x","volume":"16","author":"SK Seo","year":"1999","unstructured":"Seo, S. K., Suh, J. C., Na, G. Y., Kim, I. S. & Sohn, K. R. Kasabach-Merritt syndrome: identification of platelet trapping in a tufted angioma by immunohistochemistry technique using monoclonal antibody to Cd61. Pediatr. Dermatol. 16, 392\u2013394 (1999).","journal-title":"Pediatr. Dermatol."},{"key":"1986_CR20","doi-asserted-by":"crossref","unstructured":"Homayun-Sepehr, N. et al. KRAS-driven model of Gorham-Stout disease effectively treated with trametinib. JCI Insight 6, e149831 (2021).","DOI":"10.1172\/jci.insight.149831"},{"key":"1986_CR21","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/s41571-018-0105-0","volume":"15","author":"MB Ryan","year":"2018","unstructured":"Ryan, M. B. & Corcoran, R. B. Therapeutic strategies to target Ras-mutant cancers. Nat. Rev. Clin. Oncol. 15, 709\u2013720 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1986_CR22","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S1470-2045(17)30180-8","volume":"18","author":"R Dummer","year":"2017","unstructured":"Dummer, R. et al. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (Nemo): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 18, 435\u2013445 (2017).","journal-title":"Lancet Oncol."},{"key":"1986_CR23","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1111\/bjd.19814","volume":"184","author":"S Greenberger","year":"2021","unstructured":"Greenberger, S. et al. Agminated benign vascular tumour successfully treated with trametinib. Br. J. Dermatol. 184, 1195\u20131197 (2021).","journal-title":"Br. J. Dermatol."}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41390-022-01986-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-022-01986-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-022-01986-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T11:02:30Z","timestamp":1700650950000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-022-01986-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,4]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["1986"],"URL":"https:\/\/doi.org\/10.1038\/s41390-022-01986-0","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,4]]},"assertion":[{"value":"17 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All studies were performed following the patient\u2019s informed consent and according to the principles of the Declaration of Helsinki. Approval was obtained from Sheba Medical Center Institutional Review Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}